We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals

126 hedge funds and large institutions have $454M invested in Kiniksa Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 7

156% more call options, than puts

Call options by funds: $6.89M | Put options by funds: $2.69M

21% more funds holding

Funds holding: 104 → 126 (+22)

17% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 35

13% more capital inflows, than outflows

Capital inflows: $62.2M | Capital outflows: $55.1M

0.96% more ownership

Funds ownership: 86.8% → 87.76% (+0.96%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
126
Holders Change
+22
Holders Change %
+21.15%
% of All Funds
2.02%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
30
Increased
41
Reduced
35
Closed
7
Calls
$6.89​M
Puts
$2.69​M
Net Calls
+$4.2​M
Net Calls Change
+$1.31​M

KNSA Hedge Fund Activity: Q4 2022 in Review

126 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2022, worth a combined $454M — up 18% from $384M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new KNSA positions and 7 closed out — a net gain of 23 holders — while 41 added to existing stakes and 35 trimmed.

The largest buyer was State Street, adding an estimated $12.8M. The largest seller was Pictet Asset Management, cutting an estimated $26.3M.

  • 126 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2022, up from 104 in Q3 2022.
  • Funds reported $454M of Kiniksa Pharmaceuticals stock for Q4 2022, up 18% quarter-over-quarter.
  • 30 funds opened new Kiniksa Pharmaceuticals positions in Q4 2022 and 7 closed out, a net change of +23 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2022 was State Street, an estimated $12.8M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2022 was Pictet Asset Management, an estimated $26.3M sold.

Based on aggregated 13F filings for Q4 2022.